Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Anish B. Parikh"'
Autor:
Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Publikováno v:
Cancer Medicine, Vol 11, Iss 16, Pp 3106-3114 (2022)
Abstract Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setti
Externí odkaz:
https://doaj.org/article/5a0bc07a3300429c841ed05a5967d215
Autor:
Qian Qin, Tomi Jun, Bo Wang, Vaibhav G. Patel, George Mellgard, Xiaobo Zhong, Mahalya Gogerly-Moragoda, Anish B. Parikh, Amanda Leiter, Emily J. Gallagher, Parissa Alerasool, Philip Garcia, Himanshu Joshi, MBBS, Matthew Galsky, William K. Oh, Che-Kai Tsao
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-11 (2022)
Abstract Objectives Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine. Using real-world data, we aimed
Externí odkaz:
https://doaj.org/article/37da49ca41554ae38f0bb80d40f404bf
Autor:
Yuanquan Yang, Sherry V. Mori, Mingjia Li, Megan Hinkley, Anish B. Parikh, Katharine A. Collier, Abdul Miah, Ming Yin
Publikováno v:
Cancer Medicine, Vol 11, Iss 7, Pp 1669-1677 (2022)
Abstract Background Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy is frequently used off‐label for clear cell metastatic renal cell carcinoma (mRCC). However, limited data are available to guide such therapy. We perform
Externí odkaz:
https://doaj.org/article/2d1b6391e13b4ea189b7b81fa1e5cb75
Autor:
Amir Steinberg, Janet H. Van Cleave, Anish B. Parikh, Erin Moshier, Meng Ru, Molly Lawson, Douglas Marks, Antoinette Montelibano, Amanda Philpott, Kourtney Garner, Marilyn J. Hammer
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 13, Iss 3 (2019)
Background: Abnormal blood glucose (BG) levels during hematopoietic cell transplantation (HCT) are associated with increased infections, delayed engraftment, and prolonged hospitalization, though little is known about these associations. Materials an
Externí odkaz:
https://doaj.org/article/6124f6b04c78485abf8da88b61b3879d
Autor:
Yuanquan Yang, Sherry V. Mori, Mingjia Li, Megan Hinkley, Anish B. Parikh, Katharine A. Collier, Abdul Miah, Ming Yin
Publikováno v:
Cancer Medicine. 11:1669-1677
Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy is frequently used off-label for clear cell metastatic renal cell carcinoma (mRCC). However, limited data are available to guide such therapy. We performed a meta-analysis to charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c7cc6bbdc4aa9db9e23acf868ede7f3
https://doi.org/10.1002/cam4.4587
https://doi.org/10.1002/cam4.4587
Autor:
William Oh, Che-Kai Tsao, Anish B. Parikh, John P. Sfakianos, Alberto Martini, Matthew D. Galsky, Francesco Montorsi
Publikováno v:
Prostate Cancer and Prostatic Diseases. 24:743-749
Docetaxel is widely used in metastatic castration-resistant prostate cancer (mCRPC), however its optimal use remains unclear in the current treatment landscape. Biomarkers to predict Docetaxel toxicity may help optimize treatment selection. We aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ae6852c6ebbf49bbeb5eccc55ab11f4
https://doi.org/10.1038/s41391-021-00326-3
https://doi.org/10.1038/s41391-021-00326-3
Autor:
Matthew D. Galsky, Ming Yin, Xiaobo Zhong, Amanda Leiter, Amir Mortazavi, Philip Garcia, Steven K. Clinton, Parissa Alerasool, Qian Qin, George Mellgard, Bo Wang, Vaibhav G. Patel, Anish B. Parikh, William Oh, Emily J. Gallagher, Yuanquan Yang, Che-Kai Tsao, Edmund Folefac, Paul Monk
Publikováno v:
Am J Clin Oncol
Objectives Immune checkpoint inhibitors (ICIs) are being increasingly used across cancer types. Emergency room (ER) and inpatient (IP) care, common in patients with cancer, remain poorly defined in this specific population, and risk factors for such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8d19d70cc32210da66b8daf426f6749
https://doi.org/10.1097/coc.0000000000000793
https://doi.org/10.1097/coc.0000000000000793
Autor:
Steven K. Clinton, Amir Mortazavi, Abdul Miah, Evan Gross, Edmund Folefac, Evan T. Hall, Katharine Collier, Kaylee Oliva, Paul Monk, Megan Hinkley, Yuanquan Yang, John F. Thompson, John C. Gore, Delaney Orcutt, Joel Kramer, Duncan Hussey, Mingjia Li, Sherry Mori-Vogt, George R. Schade, Scott S. Tykodi, Sarah P. Psutka, Anish B. Parikh, Elliot Trott, Ming Yin, Daniel W. Lin
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The role of CN in the treatment of mRCC has been questioned with the recent approval of novel systemic therapy (ST) agents and the results of the CARMENA trial. Our objec...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::885ea6ab2796cd6eeb1eba01afdbabd7
https://doi.org/10.1097/ju.0000000000001995.08
https://doi.org/10.1097/ju.0000000000001995.08
Autor:
John P. Sfakianos, Nicola Fossati, Andrea Necchi, Francesco Montorsi, Anish B. Parikh, Vito Cucchiara, Alberto Briganti, Matthew D. Galsky, Alberto Martini, Che-Kai Tsao, Giorgio Gandaglia, Simone Scuderi, Armando Stabile, Francesco Pellegrino, William Oh, Pierre I. Karakiewicz, Giuseppe Cirulli
Publikováno v:
Journal of Urology. 206
INTRODUCTIONAND OBJECTIVE: Docetaxel is widely used in metastatic castration-resistant prostate cancer (mCRPC), however its optimal use remains unclear. Biomarkers and prediction models assessing e...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c13276cbf920e7bf854dd8735f0a621
https://doi.org/10.1097/ju.0000000000002015.09
https://doi.org/10.1097/ju.0000000000002015.09
Autor:
Ming Yin, Delaney Orcutt, John L. Gore, Steven K. Clinton, Sherry Mori-Vogt, Amir Mortazavi, Scott S. Tykodi, Abdul Miah, Megan Hinkley, Elliot Trott, Edmund Folefac, Daniel W. Lin, Evan T. Hall, Paul Monk, Katharine Collier, Kaylee Oliva, Yuanquan Yang, Duncan Hussey, Joel Kramer, John F. Thompson, Evan Gross, George R. Schade, Sarah P. Psutka, Anish B. Parikh, Mingjia Li
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:IO/TKI combinations are a new standard of care for the initial treatment (tx) of mRCC. Efficacy and toxicity of such combination regimens beyond the first-line (1L) setti...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79941787c3eb97417481941e379db200
https://doi.org/10.1097/ju.0000000000001995.19
https://doi.org/10.1097/ju.0000000000001995.19